Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 316 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293
View directory record Official record
Conditions
Homeostasis, Bone and Bones
Interventions
Dexlansoprazole, Esomeprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 75 Years · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

NCT05338502
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Ranitidine, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129414
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Placebo, Omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04368585
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Gastric Acid on Colonic Microbiome

NCT01901276
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Omeprazole 40 mg bid
Drug
Lead sponsor
Daniel Freedberg, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 16, 2026, 10:19 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study

NCT01335334
View directory record Official record
Conditions
H. Pylori Infection
Interventions
bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 16, 2026, 10:19 PM EDT
Completed No phase listed Observational

Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR

NCT01755221
View directory record Official record
Conditions
Laryngopharyngeal Reflux (LPR), Extraesophageal Reflux, Reflux Laryngitis, Posterior Laryngitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

NCT03936374
View directory record Official record
Conditions
Healthy
Interventions
BMS-986205, omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

NCT00931073
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

NCT01059383
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
VECAM 40/300, Esomeprazole 20 mg
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Diego, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

NCT04468815
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

NCT02365558
View directory record Official record
Conditions
Healthy
Interventions
Evacetrapib, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 16, 2026, 10:19 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

NCT00332748
View directory record Official record
Conditions
Cancer
Interventions
Oral Taxane
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Timeline
Started 2006
U.S. locations
3
States / cities
Newark, Delaware • Louisville, Kentucky • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

NCT00303264
View directory record Official record
Conditions
Dyspepsia
Interventions
dexloxiglumide, Nexium (esomeprazole)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

NCT02249936
View directory record Official record
Conditions
Healthy
Interventions
AZD1722, Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 16, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

A Study of Esomeprazole in Children With Autism

NCT03866668
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Esomeprazole
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 6 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

NCT03551691
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Omeprazole 20mg Capsule, Placebo oral capsule
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 16, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Symptom Control Satisfaction With Proton Pump Inhibitor Regimen

NCT02623816
View directory record Official record
Conditions
Heartburn
Interventions
Optimal Dosing of Omeprazole
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 16, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

NCT04337580
View directory record Official record
Conditions
Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer
Interventions
Omeprazole 80 mg twice daily
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 10:19 PM EDT